A Phase Ib Open Label Clinical Trial of Continuous Once Daily Oral Afatinib (A) Plus Sirolimus (S) in Patients (Pts) with Egfr Mutation Positive (Egfr M+) Nsclc and/or Disease Progression Following Prior Erlotinib (E) or Gefitinib (G) | Publicación